Highlighting newly approved medications that treat frown lines, plaque psoriasis, ulcerative colitis, molluscum contagiosum, and urinary tract infections.
The chief objectives are to reduce the patient’s symptom duration and severity, prevent both acute and delayed complications, and forestall an overspill of the infection to others.
Challenges include vaccine mismatches resulting from the virus’ rapid evolution and resistance to antiviral drugs, and prevention is complicated by vaccine hesitancy and other factors.
Nonprescription options remain a cornerstone of community healthcare for these pervasive diseases, offering patients accessible symptom relief.